# Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

> **NCT01634893** · PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 18 (actual)

## Conditions studied

- Refractory or Relapsed Solid Tumors

## Interventions

- **DRUG:** Sorafenib combined with Hydroxychloroquine

## Key facts

- **NCT ID:** NCT01634893
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634893, "Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01634893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*